Higher price of Covaxin in private markets needed to sustain costs: Bharat Biotech

Supply to the government of India at ₹150 per dose is a non-competitive price and clearly not sustainable in the long run, the company said

Comments

Popular posts from this blog

Viral video involving woman cop sparks controversy, plaint filed

Congress groomed me not to sit at home: Shivakumar

Infosys lays off hundreds after failing internal assessments in Mysuru